Might be enhanced in BRCA2-mutated prostate cancers. On the other hand, considering the fact that not
May very well be enhanced in BRCA2-mutated prostate cancers. Nevertheless, considering the fact that not all BRCA2-mutated individuals showed an unfavorable response to docetaxel, clonal heterogeneity on the somatic mutation…